<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157049</url>
  </required_header>
  <id_info>
    <org_study_id>Alpha-1 Registry Protocol</org_study_id>
    <nct_id>NCT04157049</nct_id>
  </id_info>
  <brief_title>Alpha-1 Research Registry</brief_title>
  <official_title>Alpha-1 Research Registry Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha-1 Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha-1 Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed
      with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers.
      The Registry was established to facilitate research initiatives and promote the development
      of improved treatments and a cure for Alpha-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose and goal of the Alpha-1 Research Registry (Registry, or group of patients) will
      be to obtain uniform, longitudinal (over the course of time), complete and accurate data that
      can be organized, and made available for the public to query. The collective number of
      Registry members enables investigators to enroll sufficient subjects to carry out their
      studies. The community benefits from having more research and potential therapies performed
      in their disease. Regular updates from patients will give objective data-points to measure
      the progression of disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">June 20, 2029</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Establish the Alpha-1 Research Registry using REDCap</measure>
    <time_frame>2 years</time_frame>
    <description>To gather accurate patient data for longitudinal prospective follow up/analysis of Alpha-1 progression.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>Alpha-1 Diagnosed Individuals</arm_group_label>
    <description>Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains &lt;40% of the identified PiZZ individuals in the US.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carriers of Alpha-1</arm_group_label>
    <description>Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains &lt;40% of the identified PiZZ individuals in the US.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The current protocol seeks to enroll 4,000 individuals of all age, race, and sex.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Alpha-1 Antitrypsin deficiency (ZZ)

          -  Alpha-1 carrier (MS)

        Exclusion :

          -  Failure to provide informed consent.

          -  Normal healthy individuals (MM)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nancy Joseph</last_name>
    <phone>305-567-9888</phone>
    <phone_ext>252</phone_ext>
    <email>njoseph@alpha1.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Randel Plant</last_name>
    <phone>305-567-9888</phone>
    <phone_ext>306</phone_ext>
    <email>rplant@alpha1.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alpha-1 Foundation</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Joseph</last_name>
      <phone>305-567-9888</phone>
      <phone_ext>252</phone_ext>
      <email>njoseph@alpha1.org</email>
    </contact>
    <investigator>
      <last_name>Jeanine D'Armiento, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AATTD</keyword>
  <keyword>ALPHA 1</keyword>
  <keyword>COPD</keyword>
  <keyword>AAT</keyword>
  <keyword>ZZ</keyword>
  <keyword>MZ</keyword>
  <keyword>CARRIER</keyword>
  <keyword>MM</keyword>
  <keyword>MS</keyword>
  <keyword>PiZZ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

